Innovations in data and AI are reshaping the biopharma industry.
With just days to go in the current presidential campaign, a greater focus on improving the nation’s health could be the deciding factor in a close election, argues Professor Michael Sparer.
The pharmaceutical company leader praised AI for boosting productivity, but noted that it’s still “all about the people.”
US Senator Bill Cassidy, MD, highlights the need to balance regulation and innovation when it comes to embracing AI in medicine.
Columbia Business School research is the first to find empirical evidence for how government intervention would shape the private healthcare market
Professor Carri Chan joined three leaders in the healthcare field at Columbia Business School's Think Bigger Innovation Summit to discuss how they are challenging the boundaries of innovation.
A new CBS study finds that public pharmacies can unlock a price advantage for the government that significantly outweighs the costs.
Columbia Business School Research Reveals That Addressing the Psychology of Secrets Can Enhance Emotional Well-Being and Social Connections
Frank R. Lichtenberg is Cain Brothers & Company Professor of Healthcare Management in the Faculty of Business Economics at the Columbia University Graduate School of Business; a Research Associate of the National Bureau of Economic Research; and a member of the CESifo Research Network. He received a BA with Honors in History from the University of Chicago and an MA and PhD in Economics from the University of Pennsylvania.
Ezra Mehlman is a managing partner at Health Enteprise Partners, a healthcare IT and services focused growth equity firm whose investors include some of the leading hospital systems and health plans across the country.
Professor Bartel is the Merrill Lynch Professor of Workforce Transformation at Columbia Business School and the Director of Columbia Business School's Workforce Transformation Initiative. She is an expert in the fields of labor economics and human resource management and has published numerous articles on employee training, human capital investments, job mobility, and the impact of technological change on productivity, worker skills, and outsourcing decisions. Bartel received the 1992 Margaret Chandler Award for Commitment to Excellence in teaching.
Neal Masia is an Adjunct Professor of Business and Economics at Columbia University and serves as a consultant and advisor to a variety of healthcare companies and healthcare-focused investment firms. Neal spent nearly 18 years rising through the ranks at Pfizer Inc, most recently as Chief Economist and Vice President of Patient and Health Impact.
Professor Cramer spent more than 25 years in the healthcare, pharmaceutical, and financial services sectors. He was Managing Director at Merrill Lynch in the Global Healthcare Investment Banking Group, and Managing Director at JPMorgan in the Corporate Finance Group providing M&A services and financing to global healthcare enterprises. Earlier, Prof. Cramer was Vice President, Corporate Planning & Development for Merck & Co., Inc. with worldwide responsibilities for strategic planning and business development.
Professor Chan teaches the MBA core Operations Management course and the MBA electives, The US Healthcare System: Structures and Strategies; Healthcare Management, Design, and Strategy; and The Analytics Advantage. Her research is in the area of healthcare operations management. Her primary focus is in data-driven modeling of healthcare systems. Her research combines empirical and mathematical modeling to develop evidence-based approaches to improve patient flow.
Professor Alex F. Mills is an expert in operations management and business analytics. His research focuses on the service sector, with a particular emphasis on healthcare. He has published in Management Science, Manufacturing & Service Operations Management, and other top business journals. Professor Mills is a member of the full-time faculty at Baruch College, and a member of the doctoral faculty at the Graduate Center, both in the City University of New York. He earned his PhD in Statistics and Operations Research from the University of North Carolina.
David is a Managing Partner with Health Enterprise Partners having joined the firm 16 years ago. Previously he was a Vice President for Susquehanna Growth Equity, a private equity group focused on growth stage technology companies. He was formerly the President and Chief Operating Officer of Onward Healthcare, Inc., a Welsh, Carson, Anderson & Stowe portfolio company. Prior to Onward, Dave was an Executive Vice President of Pinnacor, Inc., a General Atlantic portfolio company, which went public.
Linda Green is the Cain Brothers and Company Professor Emerita of Healthcare Management at Columbia Business School. She is also the Faculty Director of the Healthcare and Pharmaceutical Management Program at the business school.
Jing Dong is the DeRosa Family Associate Professor in the Decision, Risk, and Operations division at the Graduate School of Business, Columbia University. Her primary research interests are in applied probability and stochastic simulation, with an emphasis on applications in service operations management. Her current research focuses on developing data-driven stochastic modeling to improve patient flow in hospitals.
Professor Sicherman analyzes the roles of education, job training, occupational and job mobility, moonlighting and retirement in the formation of careers. He currently studies the various effects of technological change on the U.S. labor market. In addition, Sicherman works with different medical groups on using cost-benefit analysis in medical decision making. A faculty research fellow at the National Bureau of Economic Research, he is the recipient of research grants from the National Science Foundation, the U.S. Department of Labor and the Citicorp Behavioral Science Research Council.
Robert Essner is the retired chairman and CEO of Wyeth, which was one of the world's leading research-based pharmaceutical companies. He led the transformation of Wyeth into a science-based industry leader with strong positions in drugs, biotechnology, vaccines, nonprescription products and animal health. During his more than 30 years in the industry, Mr. Essner served as chairman of both U.S. and global pharmaceutical organizations.
